We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Large PACS/RIS Replacement Project Announced in Turkey

By MedImaging International staff writers
Posted on 08 Apr 2015
Image: The FujiFilm Synapse PACS (Photo courtesy of FujiFilm).
Image: The FujiFilm Synapse PACS (Photo courtesy of FujiFilm).
The Medical Park Group (Istanbul, Turkey) has concluded a five-year PACS/RIS replacement project for all 30 hospitals in the group.

The PACS system selected is the FujiFilm Europe (Duesseldorf, Germany) Synapse PACS and positions FujiFilm as the most widely used medical informatics vendor and global leader among PACS vendors.

The Synapse PACS provides radiologists with advanced visualization tools to assist radiologists, surgeons, and clinicians with diagnosis, pre-operative planning, and clinical decision support. The Synapse PACS Clinical Workflow Manager (CWM) is intended to enhance access to patient data, and improves the efficiency of the clinical reporting workflow. The Synapse PACS enables the archiving and distribution of image information from all modalities, uses next-generation Web technology, and Wavelet on-demand compression.

Yuksel Yazici, deputy director of the Biomedical Department at the Medical Park Group, said, “This supports us in our mission to provide qualified healthcare services to our international patients.”

Related Links:

FujiFilm Europe
Medical Park Group



Portable X-ray Unit
AJEX140H
Computed Tomography System
Aquilion ONE / INSIGHT Edition
Post-Processing Imaging System
DynaCAD Prostate
40/80-Slice CT System
uCT 528

Channels

Nuclear Medicine

view channel
Image: This artistic representation illustrates how the drug candidate NECT-224 works in the human body (Photo courtesy of HZDR/A. Gruetzner)

Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies

Targeted cancer therapies only work when tumor cells express the specific molecular structures they are designed to attack. In urothelial carcinoma, a common form of bladder cancer, the cell surface protein... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.